| 摘要: |
| 目的:探讨贝伐珠单抗在中低位局部进展期直肠癌新辅助放化疗治疗中的有效性及安全性。
方法:贝伐珠单抗联合FOLFOX方案的新辅助放化疗患者为观察组（n=25），FOLFOX方案新辅助放化疗患者为对照组（n=31）。观察两组的病理完全缓解率、肿瘤降期率、低位直肠癌的保肛率、常见放化疗不良反应及围手术期的主要并发症。
结果:两组的病理完全缓解率、总降期率及低位直肠癌保肛率无统计学意义（p>0.05）。观察组的高血压发生率高于对照组（44%：10% ，p=0.03）， 具有统计学意义，其他常见放化疗不良反应及围手术期的主要并发症无统计学意义（p>0.05）。
结论：贝伐珠单抗在中低位直肠癌的新辅助放化疗中有较高的安全性，没有明显增加新辅助放化疗的不良反应，没有明显增加围手术期的严重并发症。但未能提高直肠癌的病理完全缓解率、病理降期率及低位直肠癌的保肛率。 |
| 关键词: 贝伐单抗 中低位直肠癌 新辅助放化疗 |
| DOI： |
|
| 基金项目: |
|
| Efficacy and safety of bevacizumab in neoadjuvant chemradiotherapy for middle and low rectal cancer |
|
| () |
| Abstract: |
| Objective: To explore the efficacy and safety of bevacizumab combination in neoadjuvant therapy in the middle and low locally advanced rectal cancer.
Methods: Middle and low locally advanced rectal cancer patients who treated by bevacizumab and FOLFOX combination with neoadjuvant radiotherapy as the observation group , and the patients treated by FOLFOX combination with neoadjuvant radiotherapy as the control group. The pathological complete response rate, tumor downstaging rate, anal sphincter preservation rate, the incidence of adverse events and perioperation complications were compared between the two groups. The SPSS 23.0 software was used to data analysis and P <0.05 was thought to be statistical significance.
Results:There was no significant difference between the two groups in the rate of The pathological complete response rate, tumor downstaging rate and anal sphincter preservation rate（p>0.05）.Conclusions:Bevacizumab combined with neoadjuvant therapy was well tolerated in the treatment of middle and and low locally advanced rectal cancer, it did not obviously increase the adverse events of neoadjuvant therapy and perioperation complications. However, the pCR rate, tumor down staging rate and sphincter preservation rate was not improved in the comparison to the other trials that used FOLFOX in preoperative radiochemotherapy. |
| Key words: Bevacizumab,Rectal cancer,Neoadjuvant radiochemotherapy |
